glp-1 obesity drug news today 2025-10-20 trends 2025: real-world data, patient outcomes & future therapies GLP-1 Overdoses Are Rising as

Maximum Weight Loss Retatrutide Phase 2 data showed 24.2% mean weight loss at 48 weeks with 12 mg dose, the highest weight reduction reported for any single anti-obesity agent in Phase 2 trials, exceeding survodutide's 18.7%

Pharmacological interventions for binge eating: lessons from animal models, current treatments, and future directions

These findings provide evidence that the regulatory influence of endogenous GLP-1R signaling on bone resorption is likely mediated through pathways that involve calcitonin

The Rise of Compounded GLP-1 Drugs If brand-name drugs come with risks, the situation becomes even murkier when compounded medications enter the picture

That year, an estimated 8.2 million prescriptions for it were written in the U.S., more than quadruple the number just two years earlier